ADmit Therapeutics

Logo ADmit Therapeutics

Contact information

ADmit Therapeutic S.L.
Marta Barrachina
Calle Joan XIII, 10
Esplugues de Llobregat
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biomarkers
      • In vitro diagnostics
    • Therapeutic areas
      • Central nervous system
  • D. Services
    • R&D services
      • Bioinformatics
      • Genomics

ADmit Therapeutics, S.L. is a company spin-off from Bellvitge Biomedical Research Institute (IDIBELL), created in December 2017, and focused on the development and commercialization of a novel Alzheimer’s disease (AD) early detection technology.

Products and services

Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau. Therefore, our unique value proposition is that our test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next generation sequencing.

Areas of interest for future collaborations

Diagnostics, Drugs development and DNA sequencing platforms (next generation sequencing)

Biotech Sanitaria

Diagnostics and Personalised Medicine
Product / Service Type Therapeutic area Development phase
ADmit Test Biomarkers, Diagnostic Sistema nervioso central Clinical Validation